Pharmacological treatment of Raynaud's phenomenon with special reference to calcium-entry blockers.
The development of new vasoactive drugs has increased the possibilities to treat patients with digital vasospasm, known as Raynaud's phenomenon. The purpose of this paper is to give a review of recent clinical trials and also a short review of the pathophysiological reasons for each type of pharmacological treatment.
Nilsson
H
H
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000527:Alprostadil / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D011464:Epoprostenol / Q000627:therapeutic use; D006801:Humans; D005996:Nitroglycerin / Q000627:therapeutic use; D011928:Raynaud Disease / Q000188:drug therapy* / Q000503:physiopathology; D011985:Receptors, Serotonin / Q000187:drug effects; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
D000317:Adrenergic alpha-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D011985:Receptors, Serotonin; D011464:Epoprostenol; D013930:Thromboxane-A Synthase; D000527:Alprostadil; D005996:Nitroglycerin